FDA Approved Peptides: Which Are Real Medicines and Which Aren’t

“FDA approved peptides” is one of the most-searched phrases in this space, usually as a way of asking a sharper question: which of these compounds are actually approved medicines, and which are not? It is a good question, because the gap between the two is wide and the marketing around research peptides works hard to blur it. Here is the accurate picture — with the Canadian equivalent, since that is the regulator that actually applies here.

Framing. General information, not medical or legal advice. CompoundPlug compounds are research chemicals for laboratory use only, not authorized for human use in Canada. See Research Use Only.

First: FDA Is the US Regulator. In Canada It’s Health Canada.

The phrase “FDA approved” comes from the United States. The equivalent Canadian authority is Health Canada, and a compound approved there carries a DIN (Drug Identification Number). The two agencies’ approved lists overlap heavily but are not identical, and for anyone in Canada, the DIN is the status that matters. This article covers both, because the underlying question — approved drug or unverified research chemical — is the same either way.

What “Approved” Actually Means

An approved peptide drug has completed the full regulatory process: preclinical testing, phase 1 through phase 3 human trials, a formal drug application, regulatory review, and ongoing post-market surveillance. It is manufactured to pharmaceutical-grade standards, with established safety and efficacy from controlled human trials.

That is a fundamentally different thing from a compound that has never entered that process. The distinction is not a formality — it is the entire difference between a tested medicine and an untested chemical that happens to be the same molecule.

Peptides That Are Approved Drugs

There are over 80 approved peptide-based drugs. The ones most relevant to this catalog’s categories:

• Semaglutide (Ozempic, Wegovy, Rybelsus) — GLP-1 agonist, approved for type 2 diabetes and weight management.
• Tirzepatide (Mounjaro, Zepbound) — dual GLP-1/GIP agonist, same indications.
• Liraglutide (Victoza, Saxenda) — earlier GLP-1 agonist.
• Tesamorelin (Egrifta) — GHRH analog, approved narrowly for HIV-associated visceral fat, not for general use.
• Bremelanotide (Vyleesi) — the melanocortin agonist that came out of Melanotan 2 research; the first approved melanocortin agonist for sexual dysfunction.
• Insulin and its many analogs — the original peptide drug.

The pattern worth noting: approval is always for a specific indication. Tesamorelin being approved for HIV lipodystrophy does not make it an approved anti-aging or muscle compound — approval is not a general licence.

Peptides That Are NOT Approved Drugs

Many of the most-discussed research peptides have no approval as finished drugs from either the FDA or Health Canada:

• BPC-157 — never submitted for approval; no marketing authorization anywhere as a finished drug.
• TB-500 — not approved.
• CJC-1295, Ipamorelin, Sermorelin — GH secretagogues, not approved as finished drugs.
• Retatrutide — investigational; in phase 3 trials, not yet approved anywhere.
• Melanotan 2, Epithalon, MOTS-c, and most others in the research space — not approved.

A regulatory note that generates confusion: in the US, a separate compounding category exists, and a February 2026 policy change returned several previously restricted peptides (including BPC-157) to compounding access. Compounding status is not FDA approval. A compounded peptide has not completed clinical trials; it is deemed acceptable for preparation by a licensed pharmacy under physician oversight. That US-specific distinction does not change the Canadian picture, where these remain unapproved.

Why This Distinction Is the Whole Point

The reason the approved-vs-not question matters so much: an approved drug and a research-grade version of the same molecule are completely different products in every way except the molecule itself. One has been through trials, is made to pharmaceutical standards, has a known dose and verified contents, and is dispensed by a pharmacy. The other has none of that.

This is exactly why the one variable a research-chemical buyer can actually control is independent verification of purity and identity — because in the absence of regulatory oversight, third-party testing is the only thing standing between “the labelled compound” and “an unknown.” It doesn’t make an unapproved compound approved. It makes it verified, which is a different and more honest claim. Every CompoundPlug compound is HPLC-tested and mass-spec verified, with the analysis published in the COA Library.

The Bottom Line

Some peptides are fully approved medicines — the GLP-1 drugs, insulin, a handful of others — approved for specific indications and available by prescription. Most research peptides are not approved by the FDA or Health Canada as finished drugs, and are supplied as research chemicals rather than medicines. For anything approved, the route is a physician and a pharmacy. For the rest, “approved” is not the available claim — “verified” is, and only if someone actually tested it.

For how unapproved compounds are treated under Canadian law specifically, see Are Peptides Legal in Canada?

Frequently Asked Questions

This article is general regulatory information, not medical or legal advice. Approval status changes over time and differs between jurisdictions. The compounds referenced are supplied for laboratory research use only and are not authorized for human use in Canada.